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RESEARCH ARTICLE
Sorbus alnifolia protects dopaminergic neurodegeneration in Caenorhabditis
elegans
Se-Myeong Cheona, Insoo Jangb, Myon-Hee Leec, Dae Keun Kima, Hoon Jeona and Dong Seok Chaa
aCollege of Pharmacy, Woosuk University, Jeonbuk, Republic of Korea; bDepartment of Korean Internal Medicine, Woosuk University, Jeonbuk,
Republic of Korea; cDepartment of Medicine, Brody School of Medicine at East, Carolina University, Greenville, NC, USA
ABSTRACT
Context: The twigs of Sorbus alnifolia (Sieb. et Zucc.) K. Koch (Rosaceae) have been used to treat neuro-
logical disorders as a traditional medicine in Korea. However, there are limited data describing the efficacy
of S. alnifolia in Parkinson’s disease (PD).
Objective: This study was conducted to identify the protective effects of the methanol extracts of
S. alnifolia (MESA) on the dopaminergic (DA) neurodegeneration in Caenorhabditis elegans.
Materials and methods: To test the neuroprotective action of MESA, viability assay was performed after
48 h exposure to 1-methyl-4-phenylpyridine (MMPþ) in PC12 cells and C. elegans (400lM and 2mM of
MMPþ, respectively). Fluorescence intensity was quantified using transgenic mutants such as BZ555
(Pdat-1::GFP) and and UA57 (Pdat-1::GFP and Pdat-1::CAT-2) to determine MESA’s effects on DA neurode-
generation in C. elegans. Aggregation of a-synuclein was observed using NL5901 strain (unc-54p::a-
synuclein::YFP). MESA’s protective effects on the DA neuronal functions were examined by food-sensing
assay. Lifespan assay was conducted to test the effects of MESA on the longevity.
Results: MESA restored MPPþ-induced loss of viability in both PC12 cells and C. elegans (85.8% and
54.9%, respectively). In C. elegans, MESA provided protection against chemically and genetically-induced
DA neurodegeneration, respectively. Moreover, food-sensing functions were increased 58.4% by MESA in
the DA neuron degraded worms. MESA also prolonged the average lifespan by 25.6%. However, MESA
failed to alter a-synuclein aggregation.
Discussion and conclusions: These results revealed that MESA protects DA neurodegeneration and recov-
ers diminished DA neuronal functions, thereby can be a valuable candidate for the treatment of PD.
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Parkinson’s disease (PD) is a major progressive neurodegenera-
tive disorder and the prevalence rate of PD for those aged 65
and above is more than 1% (Dawson & Dawson 2002). The
main symptoms of PD are tremor, bradykinesia and rigidity
resulting from the death of dopaminergic (DA) neurons in the
substantia nigra of the midbrain as well as Lewy body accumula-
tion. The Parkinson’s symptoms can be managed with several
medications which regulate dopamine level in the brain or mimic
the dopamine effect. However, to date, there is no available treat-
ment that cures or slows down the progress of this disease.
Although the pathogenesis of PD is not completely clear,
accumulating evidence suggests that mitochondrial dysfunction
results in increased reactive oxygen species (ROS) production
and decreased ATP synthesis possibly generate the loss of dopa-
minergic cells (Trimmer & Bennett 2009). Previous studies
revealed that 1-methyl-4-phenylpyridinium ion (MPPþ) which
inhibits mitochondrial complex I activity can induce PD-like
symptoms in humans and animal models (Langston et al. 1983;
Schmidt & Ferger 2001). In addition, high levels of mitochondrial
DNA deletions and mutations were observed from PD patients
(Parker & Parks 2005; Bender et al. 2006). Therefore, preventing
mitochondrial dysfunction or reducing oxidative stress has been
considered as an attractive therapeutic target for PD treatment.
Recently, new drugs originating from natural products have
received much attention, and many plant-derived compounds
show neuroprotective properties in animal PD models. Thus,
exploration of ethnopharmacological treatments may be a cost-
effective and promising way for developing novel drugs for PD.
Recently, despite their lack of evolutionary complexity,
Caenorhabditis elegans has become a popular experimental model
system for screening drugs relevant to neurodegenerative dis-
eases, including PD with several advantages (Schmidt et al.
2007). This simple organism has eight DA neurons that can be
easily visualized by expressing a fluorescent protein, and thus,
allows identification of morphological changes during neurodege-
nerative processes. Moreover, the components and functions of
mammalian DA system are highly conserved in this simple
organism.
Sorbus alnifolia (Sieb. et Zucc.) K. Koch (Rosaceae) is also
known as Alder-leafed White beam or Korean White beam. The
bark of Sorbus species are believed to possess strong therapeutic
potential regarding neurological disorders, such as stroke and
neurological pain. However, there is no scientific evidence to
support this traditional usage. Hence, this study was undertaken
to verify the protective role of the twigs of S. alnifolia on the
pathogenesis of PD. In the present study, we tested neuroprotec-
tive potential of S. alnifolia against MPPþ-induced toxicity in
both PC12 cells and wild-type C. elegans. We also investigated
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the effects of S. alnifolia on the DA neurodegeneration and
DA-related functional characteristics in C. elegans.
Materials and methods
Plant material and extraction
The plant materials were purchased from Kangwonyakcho
(Kangwon, South Korea) in March 2012. The plant was identified
by Dr. Dae Keun Kim (College of Pharmacy, Woosuk
University). A voucher specimen (WH086) has been deposited at
the Department of Oriental Pharmacy, College of Pharmacy,
Woosuk University. The dried stems and twigs of the plant
(600 g) were extracted using 6000mL of MeOH with 2 h sonic-
ation. The resultant methanol extract (MESA) was concentrated
into 28.1 g (yield 4.68%) using a rotary evaporator. Then, MESA
was lyophilized and stored at 20 C for further use. The MESA
was initially dissolved in D.W. and diluted with M9 buffer to the
appropriate concentration.
Cell culture condition and cell viability assay
NGF-differentiated rat pheochromocytoma cells (PC12 cells) were
kindly provided by Dr. Eun Joo Bae (College of Pharmacy,
Woosuk University) and maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% heat-inactivated
fetal bovine serum, 100U/mL penicillin and 100 lg/mL strepto-
mycin in a 5% CO2 incubator at 37 C. PC12 cells were plated at a
density of 1.5 105 cells/well in 96-well plates and incubated for
24 h. Then, the cells were pretreated with MESA and incubated for
2 h. After the pretreatment period, 400lM MPPþwas added to the
culture medium. After an additional 48 h incubation, MTT assay
was performed to determine the cell viability.
C. elegans culture and maintenance
Worms were grown on the nematode growth medium (NGM)
agar plate and maintained at 20 C as described previously
(Brenner 1974). Living Escherichia coli bacteria (OP50) was added
to the surface of NGM plates for providing the food source. In
this study, wild-type Bristol N2 and transgenic strains including
BZ555 (egIs1, Pdat-1::GFP), UA57 (baIs4, Pdat-1::GFP; Pdat-
1::CAT-2), CB1112 (e1112, cat-2 loss of function), NL5901
(pkIs2386, unc-54p::alphasynuclein::YFP) were used. Bristol
N2 (wild-type) and E. coli OP50 strain were kindly provided by
Dr. Myon-Hee Lee (East Carolina University, NC, USA).
Transgenic strains were obtained from the Caenorhabditis Genetic
Center (CGC; University of Minnesota, Minneapolis, MN).
Treatment of worms with MPP1and viability assay
Age-synchronized L1 larvae were transferred to 96-well plate at
an average of 15 worms/well in a 40 lL of liquid culture solution
with concentrated OP50. Then, MPPþ (2mM) and various con-
centrations of MESA were added to make a final volume of
50 lL per well. After 48 h incubation, the worm viability was
examined under the stereo-microscope. Test worms were consid-
ered dead when they failed to respond to prodding with the tip
of a platinum wire. Each test was performed at least three times.
Analysis of dopaminergic neurodegeneration
Age-synchronized L1 larvae of BZ555 (Pdat-1::GFP) worms were
incubated with MPPþ (1mM) alone or in the presence of various
concentrations of MESA in the 96-well plate. L1 larvae of UA57
(Pdat-1::GFP and Pdat-1::CAT-2) worms were transferred to
96-well plate and incubated in the presence or absence of MESA.
On the 5th day of adulthood, either the MPPþ-treated BZ555
worms or the UA57 worms were immobilized with 200mM
sodium azide and mounted onto 2% agarose pads. The DA neu-
rodegeneration was microscopically observed using a fluorescence
microscope (Nikon Eclipse Ni-u, Japan). DA neurons were
counted in each survived animal by inspecting the GFP fluores-
cence. The data were obtained from four independent experi-
ments and expressed as the percentage of normal controls. The
fluorescence signals of DA neuron were quantified with Image J
software (NIH, Bethesda, MD) and also photographed at
200magnification.
Analysis of a-synuclein aggregation
Effects of MESA on the a-synuclein aggregation was evaluated
using NL5901 strain (pkIs2386, unc-54p::alphasynuclein::YFP) as
reported previously (Jadiya et al. 2011). Briefly, age-synchronized
worms were washed three times with M9 buffer to get rid of
remaining bacteria and mounted onto 2% agarose pads. Then,
worms were immobilized with 200mM sodium azide. To moni-
tor the a-synuclein aggregation, YFP protein was microscopically
visualized and photographed using a fluorescence microscope
(Nikon Eclipse Ni-u, Japan). The fluorescence signals were quan-
tified in each worm with Image J software (NIH, Bethesda, MD).
Food sensing assay
Well-fed worms with intact DA neural circuitry moved slower in
the presence of bacterial food than in its absence. This basal
slowing response (or food-sensing response) was assayed as
described by Sawin et al. (2000). Briefly, food-containing plates
were prepared by spreading the bacterial food OP50 and together
with non-coated plates, they were incubated at 37 C overnight
and cooled to room temperature prior to the assay. Age-
synchronized worms were transferred from their food-containing
culture plate to a non-food plate and washed in M9 buffer
(100mM NaCl, 10 lg/mL cholesterol, 50mM potassium phos-
phate, pH 6.0) three times to get rid of the remaining food. For
the food sensing assay, travel distances in both food-coated plate
and non-coated plated were measured and basal slowing
responses were calculated.
Lifespan assay
The lifespan assays were performed using N2 and NL5901
strains at 20 C. To obtain age-synchronized nematodes, eggs
were transferred to NGM plate in the absence or presence of
250 lg/mL of MESA after embryo isolation. The number of
worm was daily counted under the stereo-microscope. Test
worms were considered dead when they failed to respond to
prodding with the tip of a platinum wire. The worms were trans-
ferred to fresh NGM plate every 2 days.
Data analysis
The data from the lifespan assay were plotted using the
Kaplan–Meier analysis and statistical significance was analyzed
by the log-rank test. Other data were presented as mean ± stan-
dard deviation or standard error of the mean, as indicated.
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Statistical significance of differences between the the control and
treated groups were analyzed by one-way analysis of variance
(ANOVA).
Results
MESA reduces MPP1-induced neurotoxicity in vitro and in
vivo
In case of in vitro study, MPPþ-mediated oxidative damage in
PC12 cells has been widely used as a cellular model to explore
the possible anti-Parkinson agent (Kook et al. 2011; Li et al.
2013). The cell viability of PC12 cells was determined by MTT
assay to verify whether MESA can reduce MPPþ-induced dam-
age. The relative values (% of control in mean ± S.D.) of MPPþ-
treated cells were 48.27 ± 16.95%. In this study, MESA treatment
effectively protected MPPþ-induced cytotoxicity in a dose-
dependent manner in NGF-differentiated PC12 cells. The values
of viability of MESA-treated cells were 63.61 ± 11.76, 79.93 ± 9.22
and 85.83 ± 8.74% at 125, 250 and 500lg/mL, respectively
(Figure 1(a)). However, MESA alone did not change the cell via-
bility, indicating the lack of toxicity at the treatment concentra-
tion (Data not shown). To test whether MESA has protective
potential against MPPþ-induced toxicity in vivo, survival assay
was carried out using C. elegans model system. After
MPPþ exposure, substantial worm death occurred. The relative
value of survival rate was 26.25 ± 6.87 after the treatment of
2mM of MPPþ. As shown in Figure 1(b), pretreatment of MESA
at the dosage of 62.5, 125, and 250lg/mL significantly restored
MPPþ-induced loss of viability by 10.62%, 21.85%, and 54.93%,
respectively. However, MESA alone did not change the survival
rate of worms. These observed results indicated that MESA has
protective potential against MPPþ-mediated neurotoxicity.
MESA protects DA neurodegeneration in C. elegans
To investigate whether MESA could reduce MPPþ-induced DA
neurodegeneration, normality of DA neurons was analyzed using
transgenic strain BZ555, expressing GFP in the DA neurons.
In this study, control worms exhibited bright GFP fluorescence
in the cell bodies and dendrites from the nerve ring to the tip of
nose. In contrast, as can be seen in Figure 2(a), 4 days of
MPPþ (1mM) exposure to worms caused a typical MPPþ-
induced degeneration of DA neurons. The MESA significantly
elevated the resistance of DA neurons to MPPþ at all treated
concentration of MESA (Figure 2(c)). Since over-expression of
cat-2 gene, a tyrosine hydroxylase homolog, is believed to induce
DA neurodegeneration, we further checked MESA’s possible pro-
tective effects on the loss of DA neurons in the CAT-2 protein
over-expressing transgenic strain UA57. Excessive CAT-2 protein
in DA neurons causes degeneration at all developmental stages,
but becomes more pronounced as animals age. On the 7th day of
adulthood, DA neurons of UA57 worms were degraded signifi-
cantly (Figure 2(b)). The MESA was found to suppress this DA
neurodegeneration 16.07% at 250lg/mL (Figure 2(d)). These
results showed that MESA has potent protective properties on
the DA neurodegeneration induced both chemically and
genetically.
MESA failed to prevent a-synuclein aggregation in
C. elegans
Previous discoveries have noted that pathological a-synuclein
aggregation is associated with DA neurodegeneration (Farrer
et al. 2004). Since C. elegans does not express a homolog of
a-synuclein, we used transgenic strain NL5901 expressing human
a-synuclein to investigate possible involvement of a-synuclein
attenuation in the MESA-mediated DA neuroprotection. In this
work, we could not detect significant differences in YFP fluores-
cence signals between MESA-treated and vehicle-treated worms,
suggesting no effect of MESA on the a-synuclein accumulation
(Figure 3(a,b)).
MESA restores DA-specific behaviuoral dysfunction in the
MPP1-treated C. elegans
In order to elucidate whether MESA-mediated DA neuroprotec-
tion was potent enough to rescue decreased DA-related func-
tional characteristics, food-sensing assay was conducted under
MPPþ-supplemented condition. When worms come across food
(OP50), they decelerate the bending frequency to feed themselves
more effectively via sensing the food by DA neurons. Thus, DA
neuron-degraded worm shows defected food-sensing behaviour.
Herein, wild-type worms showed a decrease in travel distance
71.65% upon exposure to OP50, whereas worms deficient in
cat-2 (e1112) almost completely lost the slowing in response to
food, as consistent with previous observation (Sawin et al. 2000).
In addition, MPPþ-treatment also appeared to reduce food-
sensing response about 20%, compared to vehicle-treated worms.
Figure 1. Protective effects of MESA against MPPþ-induced toxicity. (A) PC12 cells plated at a density of 1.5 105 cells/well and pretreated with MESA. After 2 h incu-
bation, 400lM of MPPþwas added to the culture medium and incubated for 48 h. MTT assay was performed to determine the cell viability. (B) Worms were treated
with 2mM of MPPþ for 48 h and MESA was added 30min before MPPþ treatment. Data are expressed as the mean± S.D. and results are obtained from three inde-
pendent assays with triplicate determinations. Significance of difference between MESA treatment and MPPþ-treated control was determined by a one-way ANOVA,
followed by a Tukey mean comparison post hoc test. #p< 0.05 compared with vehicle alone. p< 0.01 compared with MPPþ-treated control.
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Interestingly, MESA-fed worms rescued DA-specific behavioural
deficit in a dose-dependent manner (Figure 4).
MESA increases the lifespan of C. elegans
Since PD shares pathological features with aging, we further
investigated the effect of MESA on the longevity of worms. The
cumulative survival patterns was calculated by the Kaplan–Meier
analysis and is shown in Figure 5(a). The mean lifespan of
vehicle-treated worms was 13.55 ± 1.50 days, whereas MESA
treatment efficiently prolonged the mean lifespan of wild-type
worms up to 25.6% (Figure 5(b)). This result indicated that
MESA possesses lifespan-extension properties as well as neuro-
protective activities. However, no statistical significance was dem-
onstrated when comparing MESA and vehicle treatment in the
NL5901 transgenic worms (Figure 5(b)). This result corresponds
with our observation that MESA has no effect on the a-synuclein
aggregation.
Discussion
Environmentally, damage of DA neurons can be caused by
exposure to toxic substances, such as MPPþ and 6-hydroxydop-
amine (6-OHDA). High-affinity binding of these toxins to DA
transporters (DAT) explains preferential targeting of DA neurons
(Schober 2004). In this study, we first tested the effect of MESA
on MPPþ-induced neurotoxicity in PC12 cells. The differentiated
PC12 cells are known to have physiological properties of DA
neurons (Takashima & Koike 1985). In agreement with previous
studies, MPPþ induced death of PC12 cells and MESA efficiently
Figure 2. Protective effects of MESA on the DA neurodegeneration in C. elegans. GFP expression patterns of MPPþ-treated transgenic strain BZ555 (Pdat-1::GFP) (A)
and UA57 (Pdat-1::GFP and Pdat-1::CAT-2) (B). The fluorescence signals of DA neuron were photographed at 200magnification using fluorescence microscope. All
eight DA neurons were counted in each survived animal by inspecting the GFP fluorescence of BZ555 (C) and UA57 (D), respectively. Data are expressed as the
mean± S.E.M. and results are obtained from three independent assays. Significance of difference between MESA treatment and control was determined by a one-way
ANOVA. ###p< 0.001 compared with vehicle alone, p< 0.05 and p< 0.001 compared with control.
Figure 3. Effects of MESA on the a-synuclein aggregation in C. elegans.
Aggregation of a-synuclein protein was observed using transgenic strain NL5901
(pkIs2386, unc-54p::alphasynuclein::YFP). (A) YFP protein was microscopically
visualized and photographed using a fluorescence microscope. (B) The fluores-
cence intensity was quantified with Image J software. Data are expressed as the
mean± S.E.M. and results are obtained from three independent assays.
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attenuated this MPPþ-mediated cell toxicity. To further examine
the protective effect of MESA in in vivo conditions, we investi-
gated the survival rate against MPPþ insult using C. elegans
model system. Similar to the results in PC12 cells, MPPþ-medi-
ated loss of worm survival was significantly recovered by MESA
supplementation.
Similar to mammals, MPPþ exposure to C. elegans induces
accumulation of MPPþ in the DA neurons resulting in inactiva-
tion of mitochondrial transport chain complex I, thereby causing
selective death of DA neurons (Braungart et al. 2004).
Mitochondrial dysfunctions induced by MPPþ result in the gen-
eration of ROS, and finally leading to apoptosis of DA neurons
via caspase activation (Liou et al. 2005; Dias et al. 2013). In this
study, worms without MPPþ showed vivid GFP fluorescence in
all four cephalic sensilla (CEP) dendrites, while MPPþ-treated
worms displayed a significant GFP loss, indicating DA neurode-
generation. We found that this MPPþ-mediated neuronal damage
in CEP dendrites was prevented in the presence of MESA. Our
unpublished data suggest that MESA possesses strong radical
scavenging capacity, and thus, the neuroprotective effect of
MESA could probably be associated with its antioxidant poten-
tial. However, additional study is necessary to determine the role
of MESA in the caspase activation triggered by mitochondrial
dysfunction.
In addition to exogenous factors favouring the formation of
ROS, DA neurons are also susceptible to oxidative stress as
a result of disturbance of DA metabolism (Blum et al. 2001). In
C. elegans, cat-2 gene encodes the nematode homolog of tyrosine
hydroxylase, which is required for the DA biosynthesis. However,
over-expression of CAT-2 protein in DA neurons is associated
with age-dependent DA neurodegeneration (Cao et al. 2005). As
previously noted, we found that DA neurons (CEPs) got
damaged by excessive CAT-2 expression. In this study, CAT-2-
associated DA neuronal loss was efficiently prevented in the
MESA-treated worms, reflecting role for MESA in diminishing
oxidative stress caused by excess internal dopamine synthesis.
Thus, it seems like MESA protects DA neurons regardless of dir-
ect DAT modification, because CAT-2 overexpression, unlike
MPPþ, overproduces dopamine intracellularly. Additionally, in
the current study, MESA failed to inhibit a-synuclein aggrega-
tion, suggesting MESA does not influence the chaperoning and
vesicle trafficking activity. This result also supports the hypoth-
esis that the MESA exerts neuroprotection by a DAT-independ-
ent mechanism, because a-synuclein-induced DA
neurodegeneration is closely associated with DAT regulation
(Cao et al. 2005; Butler et al. 2015).
Previous studies suggest that one of the roles of DA neuro-
transmission in C. elegans involves adaptive behaviour in food-
sensing (Sawin et al. 2000). When worms enter the food area,
CEP neurons sense surrounding bacteria and the worms and
hence decrease crawling velocity to facilitate food ingestion,
namely basal slowing response. In this study, MPPþ-treated
worms manifest abnormal food sensing phenotype due to dam-
age in DA neurons. Interestingly, this abnormal behavioural
phenotype was significantly recovered by MESA treatment, indi-
cating MESA can improve not just survival but also the function
of DA neuron.
Figure 5. Effects of MESA on the lifespan of C. elegans. Worms were grown in the NGM agar plate at 25 C in the absence or presence of MESA after embryo isolation.
The mortality of each group was determined by daily counting of surviving and dead animals. (A) The lifespan of MESA-treated (250lg/mL) N2 and NL5901 worms
was plotted as a survival curve using Kaplan-Meier analysis. (B) The mean lifespan of worms was calculated from the survival curves and data are expressed as the
mean± S.E.M. Statistical difference between the curves was analyzed by the log-rank test. Differences compared to the control were considered significant atp< 0.001.
Figure 4. Effects of MESA on the defected food-sensing response in MPPþ-
treated C. elegans. Travel distances in the both of food-coated plate and non-
coated plated were measured and basal slowing response were calculated. An
automated behaviour-tracking system was used for tracking and recording of
travel distances of worms. The CB1112 mutant strain was used as negative con-
trol. Data are expressed as mean ± S.E.M. and results are obtained from three
independent assays. Significance of difference between MESA treatment and
MPPþ-treated control was determined by a one-way ANOVA. ###p< 0.001 com-
pared with vehicle control. p< 0.01 and p< 0.001 compared with MPPþ-
treated control.
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Accumulated evidence demonstrated that aging may be rele-
vant to PD (Levy 2007). Indeed, elderly PD patients showed a
faster rate of motor impairment, reduced levodopa responsiveness
and more severe cognitive dysfunction (Gomez Arevalo et al.
1997; Katzen et al. 1998; Yankner et al. 2008). Therefore, aging-
related genes may be an effective therapeutic target for PD. Our
observations of prolonged lifespan in MESA-treated worms led us
to postulate the involvement of aging-related genes in MESA’s
neuroprotective potential. Previously, dozens of genes that blocks
a-synuclein inclusion were identified in C. elegans and some of
them also participated in longevity regulation (van Ham et al.
2008). Herein, MESA failed to extend the lifespan of a-synuclein
expressing transgenic worms, implying these genes were not
required for MESA’s neuroprotective activity. However, further
investigations are required to elucidate the target genes of MESA.
Conclusions
The current study demonstrated that MESA has potent neuro-
protective properties against MPPþ-induced DA neuronal tox-
icity in vitro and in vivo. In C. elegans MESA efficiently
prevented DA neurodegeneration in both MPPþ-treated worms
and cat-2 gain of function mutants. MESA also rescued the DA
specific behavioural deficit in the MPPþ-treated worms.
Additionally, MESA exhibited lifespan-extension effects in wild-
type worms. In conclusion, MESA might be a valuable candidate
for the treatment of PD.
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